[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363278-105":59,"doc-detail-363278-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","early-stage-multi-cancer-detection-through-a-plasma-extracellular-vesicle-protein-signature","Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature","","Small extracellular vesicles (sEVs) provide a non-invasive approach for cancer detection, but translation into reliable diagnostics remains challenging. This study develops a 4-protein sEV biomarker panel (thrombospondin-1, nidogen-1, pentraxin-3, and versican) from an isogenic cancer cell model and validates performance across 22 cancer cell lines and 764 retrospective plasma/serum samples. A multiplex nanoshearing microfluidic SERS device enables simultaneous marker readout and, in a prospective cohort of 68 patients, distinguishes benign lung changes from early-stage lung cancer with strong accuracy.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/early-stage-multi-cancer-detection-through-a-plasma-extracellular-vesicle-protein-signature/363278/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/early-stage-multi-cancer-detection-through-a-plasma-extracellular-vesicle-protein-signature/363278.png","ImageObject",300,407,{"name":92,"@type":93},"Pentious","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What biomarker panel is proposed for early-stage multi-cancer detection?","Question",{"text":113,"@type":114},"The study identifies a 4-protein small extracellular vesicle biomarker panel: thrombospondin-1, nidogen-1, pentraxin-3, and versican.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How is the biomarker panel validated?",{"text":118,"@type":114},"Performance is validated across 22 cancer cell lines and 764 retrospective plasma/serum samples spanning multiple cancer types.",{"name":120,"@type":111,"acceptedAnswer":121},"What device is developed to translate the biomarker panel clinically?",{"text":122,"@type":114},"A multiplex sEV device integrates nanoshearing-based microfluidics with surface-enhanced Raman scattering (SERS) for simultaneous detection of the four proteins.",{"name":124,"@type":111,"acceptedAnswer":125},"Can the approach differentiate early-stage lung cancer from benign lung changes?",{"text":126,"@type":114},"Yes. Using the device on a prospective cohort of 68 patients, it accurately distinguishes benign lung changes from early-stage lung cancer.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},363278,1790388575,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":31,"preview_page_count":19,"preview_urls":149},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nEarly-stage multi-cancer detection through a plasma extracellular vesicle protein signature  \nGraphical abstract  \nHighlights  \n• Protein markers in small extracellular vesicles discovered via an isogenic cell model  \nAuthors  \nRichard J. Lobb, Quan Zhou,  \nDavid Fielding, ..., Andrew P. Barbour, Matt Trau, Andreas M¨oller  \nCorrespondence  \n[richard.lobb@uq.edu.au](richard.lobb@uq.edu.au) (R.J.L.), [m.trau@uq.edu.au](m.trau@uq.edu.au) (M.T.),  \n[andreas.moeller@ent.cuhk.edu.hk](andreas.moeller@ent.cuhk.edu.hk) (A.M.)  \nIn brief  \nLobb et al. identify a 4-protein small extracellular vesicle signature for earlystage cancer detection and validate in 22 cell lines and 764 clinical samples spanning 9 cancer types. The signature is integrated with a multiplex microfluidic SERS device that distinguishes malignant from benign lung lesions, enabling scalable, noninvasive screening.  \n• Validation in 22 cell lines and 764 clinical samples across multiple cancer types  \n• Integration with a microfluidic SERS device allows simultaneous marker readout  \n• Accurate differentiation of early-stage malignant from benign lung nodules  \nLobb et al., 2026, Cell Reports Medicine 7, 102694  \nApril 21, 2026 © 2026 The Authors. Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2026.102694](https://doi.org/10.1016/j.xcrm.2026.102694)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nEarly-stage multi-cancer detection through a plasma extracellular vesicle protein signature  \nRichard J. Lobb,1,2,23,* Quan Zhou,1,23 David Fielding,3 Kekoolani S. Visan,4,5 Alain Wuethrich,1,6 Jing Wang,1 Youran Hu,1 Emma L. Norris,7 Marcus L. Hastie,7 Sarah Everitt,8,9 Brielle Parris,10,11 Lauren G. Aoude,12 Vanessa F. Bonazzi,12 Elizabeth Nixon,3 Jennifer Mooi,13,14 Kevin M. Koo,1,15 Kenneth O’Byrne,16 Arutha Kulasinghe,12 RayleenV. Bowman,10,11 Ian A. Yang,10,11 Niall M. Corcoran,17,18,19 Christopher M. Hovens,17 Michael MacManus,8,9 Jeffrey J. Gorman,7  \nBryan W. Day,20 Gunter Hartel,21 David C. Whiteman,22 Niall Tebbutt,13,14 John M. Mariadason,13,14 Kwun M. Fong,10,11 Andrew P. Barbour,12 Matt Trau,1,6,* and Andreas M¨oller2,4,5,24,*  \n1Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia  \n2Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia  \n3Department of Thoracic Medicine, Royal Brisbane and Women’s Hospital, Brisbane, QLD 4029, Australia  \n4JC STEM Lab, Department of Otorhinolaryngology, Chinese University of Hong Kong, Shatin, Hong Kong SAR  \n5Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Shatin, Hong Kong SAR  \n6School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia  \n7Protein Discovery Centre, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia  \n8Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia  \n9Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3052, Australia  \n10UQ Thoracic Research Centre, The University of Queensland, Brisbane, QLD 4072, Australia  \n11The Prince Charles Hospital, Brisbane, QLD 4032, Australia  \n12Frazer Institute, The University of Queensland, Brisbane, QLD 4102, Australia  \n13Olivia Newton-John Cancer Research Institute, Melbourne, VIC 3084, Australia  \n14School of Cancer Medicine, La Trobe University, Melbourne, VIC 3084, Australia  \n15The University of Queensland Centre for Clinical Research (UQCCR), Brisbane, QLD 4029, Australia  \n16School of Medicine, Queensland University of Technology, Brisbane, QLD 4102, Australia  \n17Department of Surgery, University of Melbourne, Melbourne, VIC 3010, Australia  \n18Division of Urology, Royal Melbourne Hospital, Melbourne, VIC 3052, Australia  \n19Department of Urology, Peninsula Health, Melbourne, VIC 3199, Australia  \n20Sid Faithfull Brain Cancer Laboratory, QIMR Berghofer ","cbCaiafencADObcm","https://ap.wps.com/l/cbCaiafencADObcm","pdf",6766470,"English","# Highlights\n## Summary\n# Introduction\n# Methods and validation (cell lines and clinical samples)\n# Multiplex microfluidic SERS device\n# Clinical differentiation and screening potential","[{\"question\":\"What biomarker panel is proposed for early-stage multi-cancer detection?\",\"answer\":\"The study identifies a 4-protein small extracellular vesicle biomarker panel: thrombospondin-1, nidogen-1, pentraxin-3, and versican.\"},{\"question\":\"How is the biomarker panel validated?\",\"answer\":\"Performance is validated across 22 cancer cell lines and 764 retrospective plasma/serum samples spanning multiple cancer types.\"},{\"question\":\"What device is developed to translate the biomarker panel clinically?\",\"answer\":\"A multiplex sEV device integrates nanoshearing-based microfluidics with surface-enhanced Raman scattering (SERS) for simultaneous detection of the four proteins.\"},{\"question\":\"Can the approach differentiate early-stage lung cancer from benign lung changes?\",\"answer\":\"Yes. Using the device on a prospective cohort of 68 patients, it accurately distinguishes benign lung changes from early-stage lung cancer.\"}]","Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature | PDF",1790150604,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d95d1c6ed64e72fd6b1f56fd3778f89.webp",983,1276,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b55fb3f29db67392dfd5fe4de606d8a.webp",982,1275,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07cf382428b404993f485b055953d4e6.webp",981,1273,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e096d15ebac2440c979e262154debe9.webp",980,1272]